Landmark Phase III Trial Reveals Oral Drug Daraxonrasib Nearly Doubles Survival in Advanced Pancreatic Cancer

Published: June 9, 2026

CHICAGO — In what leading oncologists are calling the most significant therapeutic breakthrough for pancreatic cancer in a half-century, a novel oral medication has been shown to nearly double the survival time of patients battling advanced metastatic disease. Data from the landmark Phase III RASolute-302 clinical trial, presented at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO) and published simultaneously in The New England Journal of Medicine, reveal that the targeted therapy daraxonrasib drastically outpaces standard chemotherapy. For a patient population long burdened by dismal prognoses and limited treatment options, these findings represent an unprecedented shift in the therapeutic landscape.

Turning Off the “Undruggable” Light Switch

To understand the clinical significance of daraxonrasib, one must understand the genetic architecture of pancreatic cancer. Approximately 90% of pancreatic ductal adenocarcinomas (PDAC)—the most prevalent form of the disease—are driven by mutations in the KRAS gene. Discovered more than four decades ago, the KRAS protein was long considered “undruggable” by structural biologists and pharmacologists alike due to its smooth, featureless surface.

“The KRAS protein is like a shiny ball, and you can’t stick any agent to it,” explained Dr. Shubham Pant, M.D., a gastrointestinal oncologist at MD Anderson Cancer Center in Houston and a co-author of the study. “This drug is truly a breakthrough as it can target the undruggable.”

Daraxonrasib belongs to an innovative class of therapeutic agents known as RAS(ON) inhibitors. Rather than trying to bind to an inaccessible pocket, the drug operates as “molecular glue.” It is a multi-selective, non-covalent inhibitor that specifically targets the active, GTP-bound (“on”) form of RAS proteins driving malignant cell proliferation.

Oncologists often utilize a simple analogy to explain this mechanism: in healthy tissue, the RAS protein acts like a light switch that regulates cell growth. In pancreatic cancer, a KRAS mutation wedges that switch permanently in the “on” position, flooding the body with continuous cellular growth signals. Daraxonrasib acts like Velcro, adhering tightly to the active switch, forcing it into the “off” position, and triggering cancer cell death. Crucially, while earlier targeted therapies focused on single, narrow KRAS subtypes (such as G12C), daraxonrasib’s multi-selective design allows it to inhibit a broader spectrum of RAS-driven aberrations.

Staggering Survival Gains in the RASolute-302 Trial

The international, randomized Phase III RASolute-302 trial evaluated the efficacy of the once-daily oral pill against standard-of-care second-line chemotherapy. The trial enrolled patients with previously treated metastatic PDAC who had already progressed after a first line of systemic chemotherapy.

The survival data sent shockwaves through the oncology community:

• Median Overall Survival: Patients receiving daraxonrasib achieved a median overall survival of 13.2 months, compared to just 6.7 months for those in the standard chemotherapy arm—a near-doubling of life expectancy.

• Risk Reduction: The investigative treatment reduced the overall risk of death by approximately 60% when compared directly to traditional cytotoxic chemotherapy.

• Mutation-Specific Efficacy: In the cohort presenting with specific RAS G12 mutations, the survival advantage held firm at a median of 13.2 months versus 6.7 months.

“For pancreatic cancer, we’ve done a lot of trials, and they’ve failed,” Dr. Pant remarked. “Even in trials that showed any advantage, it typically resulted in only a few weeks to months of improvement. And this drug doubled the survival.”

Benefits Beyond Survival: A Rare Victory for Quality of Life

In advanced pancreatic oncology, extending life is only half the battle; preserving the quality of that extended life is equally vital. Advanced pancreatic cancer is an aggressive disease characterized by severe abdominal pain, profound cachexia (muscle wasting and weight loss), and severe malabsorption or indigestion.

Data from patient-reported outcomes (PROs) in the RASolute-302 trial revealed that daraxonrasib significantly palliated these debilitating symptoms. Patients reported:

• Substantial reductions in baseline cancer pain

• Improved appetite and subsequent weight stabilization or lean mass gain

• Increased levels of daily physical activity

• Marked improvements in digestive comfort

Because the drug successfully shrank primary and metastatic tumors, the mechanical and metabolic burdens of the disease were lifted. Furthermore, investigators noted that patients on the targeted therapy required fewer opioid medications for pain management than those on standard chemotherapy.

“Survival is just one thing, which is very important,” Dr. Pant noted. “But pancreatic cancer is a tough disease… What we saw in this trial was that patient-related outcomes dramatically improved on daraxonrasib. As a result, patients actually felt better while they were on the therapy, which you never hear.”

Safety, Side Effects, and Tolerability

As an oral targeted agent, daraxonrasib avoids many of the traditional, systemic toxicities associated with cytotoxic chemotherapy. Patients undergoing treatment do not typically experience hair loss (alopecia) or severe bone marrow suppression (low blood cell counts), which frequently leave chemotherapy patients vulnerable to dangerous infections and profound fatigue.

However, the drug does present a distinct side-effect profile that requires clinical management:

“I’ve treated patients with this drug, and it’s actually fairly tolerable, so patients can preserve their quality of life,” said Dr. Wells Messersmith, Associate Director of the University of Colorado Cancer Center and head of the Medical Oncology division at the University of Colorado Anschutz School of Medicine, who was not involved in the study.

The Public Health Context: Confronting a “Stabby Foe”

The emergence of daraxonrasib arrives at a critical juncture for public health. According to the American Cancer Society, pancreatic cancer remains the third-leading cause of cancer-related mortality in the United States, projected to claim an estimated 52,740 lives in 2026. It holds the somber distinction of being the deadliest major malignancy, with a combined five-year survival rate of just 13% across all stages.

For those diagnosed with metastatic disease—which accounts for roughly 80% of all cases due to a persistent lack of early symptoms or screening tools—the five-year survival rate plummets to approximately 3%. Historically, when a patient’s metastatic disease progressed past initial chemotherapy, subsequent treatment lines offered a bleak median survival of roughly six months. Daraxonrasib fundamentally disrupts this narrative.

HISTORICAL VS. NEW SURVIVAL LANDMARK (Second-Line Metastatic PDAC)
Standard Chemotherapy: ███████ 6.7 months
Daraxonrasib Oral:     ██████████████ 13.2 months (~2x Increase)

Current Regulatory Status and Global Accessibility

Recognizing the urgent unmet medical need, the U.S. Food and Drug Administration (FDA) previously granted daraxonrasib both Breakthrough Therapy Designation and Orphan Drug Designation. Moving swiftly following the trial’s unblinding, the FDA greenlit an Expanded Access Program (EAP) effective May 1, 2026. This pathway allows oncologists to request the drug directly from its manufacturer, Revolution Medicines, for eligible pancreatic cancer patients who have exhausted their first line of chemotherapy while full regulatory review is completed.

While full FDA approval is anticipated by the end of 2026, global access remains a prominent concern for public health advocates.

“In America, it’s with the FDA,” Dr. Pant explained. “They’re obviously gonna look at the trial, we know the results, but we still need approval. So right now, we do not have that access to treat our patients with it [globally]. But hopefully, it’ll get approved by the FDA.”

Limitations and Future Horizons

Despite the euphoria surrounding the ASCO presentation—where lead investigator Dr. Brian Wolpin of the Dana-Farber Cancer Institute received a rare standing ovation from normally reserved scientific peers—experts stress that daraxonrasib is a major advancement, but not a cure.

“It’s not a cure, which is the ultimate goal,” cautioned Dr. Messersmith. “But it adds substantial benefit with fairly manageable side effects.”

To build upon this success, researchers have already initiated the global RASolute-303 trial. This study moves daraxonrasib into the frontline setting, evaluating it both as a standalone agent and in combination with standard frontline chemotherapy (gemcitabine and nab-paclitaxel) in newly diagnosed patients. Additional global clinical trials are underway to test the drug’s efficacy in earlier, resectable stages of pancreatic cancer following surgery, as well as in other deadly, RAS-mutant solid malignancies, including non-small cell lung cancer (NSCLC) and colorectal cancer.

Beyond the immediate clinical benefits, the success of daraxonrasib is expected to catalyze a wave of pharmaceutical innovation.

“As other drug companies learn from the breakthrough, they will probably develop variations on its theme, ones that are more effective and with fewer side effects,” Dr. Messersmith noted. “A sort of arms race happens, which is good for patients, because competition means more access, more options, and also potential price competition down the line.”

Medical Disclaimer

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• https://www.ndtv.com/health/exclusive-biggest-pancreatic-cancer-breakthrough-in-50-years-says-indian-doctor-co-author-of-global-clinical-trial-11595790